[go: up one dir, main page]

SG10201403758SA - Methods and compositions for use in cellular therapies - Google Patents

Methods and compositions for use in cellular therapies

Info

Publication number
SG10201403758SA
SG10201403758SA SG10201403758SA SG10201403758SA SG10201403758SA SG 10201403758S A SG10201403758S A SG 10201403758SA SG 10201403758S A SG10201403758S A SG 10201403758SA SG 10201403758S A SG10201403758S A SG 10201403758SA SG 10201403758S A SG10201403758S A SG 10201403758SA
Authority
SG
Singapore
Prior art keywords
compositions
methods
cellular therapies
therapies
cellular
Prior art date
Application number
SG10201403758SA
Inventor
Eleuterio Lombardo
Dirk Buscher
Original Assignee
Tigenix S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix S A filed Critical Tigenix S A
Publication of SG10201403758SA publication Critical patent/SG10201403758SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
SG10201403758SA 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies SG10201403758SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22427509P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
SG10201403758SA true SG10201403758SA (en) 2014-10-30

Family

ID=42782196

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012001574A SG177582A1 (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies
SG10201403758SA SG10201403758SA (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012001574A SG177582A1 (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies

Country Status (19)

Country Link
US (1) US8679834B2 (en)
EP (2) EP3150703A1 (en)
JP (1) JP5892931B2 (en)
KR (1) KR101788885B1 (en)
CN (2) CN107007626A (en)
AU (1) AU2010269962B2 (en)
BR (1) BR112012000534A2 (en)
CA (1) CA2767300C (en)
DK (1) DK2451943T3 (en)
ES (1) ES2479542T3 (en)
HU (1) HUE031921T2 (en)
IL (1) IL217377A (en)
MX (1) MX359639B (en)
NZ (1) NZ597975A (en)
PL (1) PL2451943T3 (en)
PT (1) PT2451943T (en)
RU (1) RU2610427C2 (en)
SG (2) SG177582A1 (en)
WO (1) WO2011004264A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
JP5925408B2 (en) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． Cell population having immunomodulatory activity, isolation methods and uses
WO2011006029A1 (en) 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
US11090363B2 (en) 2009-07-10 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Vasoactive intestinal peptide release from microparticles
KR101900664B1 (en) * 2011-01-12 2018-09-21 타이제닉스, 에스.에이.유. Adipose-derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases
CN104136034B (en) 2011-11-30 2018-04-24 安斯泰来再生医药协会 Mesenchyma stromal cells and its associated uses
EP2833896A2 (en) * 2012-03-30 2015-02-11 University Of Southern California Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation
CA2876499C (en) 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US10258652B2 (en) 2014-12-18 2019-04-16 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
WO2016107563A1 (en) * 2014-12-29 2016-07-07 西比曼生物科技（上海）有限公司 Fatty mesenchymal progenitor cell complex for treating upper respiratory tract illnesses
CN107864627A (en) 2015-03-23 2018-03-30 普拉里斯坦有限公司 Include the method and composition of adhering substrate cell
EP3416662B1 (en) 2016-02-18 2020-07-29 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
EP3478300B1 (en) 2016-06-30 2022-08-24 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CN110709091A (en) 2017-05-15 2020-01-17 干细胞医药有限公司 Treatment of multiple sclerosis using long-acting glatiramer and adipose-derived stem cells
WO2018211498A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
CN107349419A (en) * 2017-07-17 2017-11-17 广东颜值科技有限公司 A kind of cell composition and its preparation method and application
CN107281469A (en) * 2017-07-17 2017-10-24 广东颜值科技有限公司 A kind of cell composition and its preparation method and application
EP3851112A4 (en) * 2018-09-14 2022-07-27 Luca Science Inc. Transplantation of mitochondria into lymphoid organ and composition therefor
AU2020240049A1 (en) * 2019-03-19 2021-11-04 Figene, Llc Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
WO2021207192A1 (en) * 2020-04-08 2021-10-14 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006951A1 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
BRPI0317064B8 (en) * 2002-12-06 2021-05-25 Northwest Biotherapeutics Inc compositions comprising dendritic cells partially matured in vitro
JP5925408B2 (en) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． Cell population having immunomodulatory activity, isolation methods and uses
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
US20090324609A1 (en) * 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US20110262402A1 (en) * 2007-09-07 2011-10-27 Masahiko Kuroda Therapeutic and prophylactic agents for arthritis
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology METHODS AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE
GB0814249D0 (en) 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells

Also Published As

Publication number Publication date
PT2451943T (en) 2017-01-20
CA2767300C (en) 2020-01-07
RU2610427C2 (en) 2017-02-10
CN107007626A (en) 2017-08-04
PL2451943T3 (en) 2017-04-28
EP2451943B1 (en) 2016-11-23
RU2012104529A (en) 2013-08-20
AU2010269962B2 (en) 2016-04-14
WO2011004264A1 (en) 2011-01-13
JP2012532859A (en) 2012-12-20
MX359639B (en) 2018-10-04
JP5892931B2 (en) 2016-03-23
MX2012000396A (en) 2012-07-17
ES2479542T1 (en) 2014-08-20
AU2010269962A1 (en) 2012-03-01
US20120308585A1 (en) 2012-12-06
HUE031921T2 (en) 2017-08-28
NZ597975A (en) 2014-06-27
CN102549147A (en) 2012-07-04
SG177582A1 (en) 2012-03-29
US8679834B2 (en) 2014-03-25
KR101788885B1 (en) 2017-10-20
CA2767300A1 (en) 2011-01-13
IL217377A0 (en) 2012-02-29
KR20120051006A (en) 2012-05-21
EP3150703A1 (en) 2017-04-05
IL217377A (en) 2017-10-31
ES2479542T3 (en) 2017-05-26
DK2451943T3 (en) 2017-02-06
EP2451943A1 (en) 2012-05-16
BR112012000534A2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
SG10201403758SA (en) Methods and compositions for use in cellular therapies
PT2272339E (en) Methods and compositions for use with gel dispensers
EP2536293A4 (en) Methods and compositions for use in aquaculture
HK1172401A1 (en) Materials for use in ophthalmic applications and methods
HUE039967T2 (en) Lipopeptide compositions and related methods
IL218212A0 (en) Therapeutic methods and compositions
PH12013500698A1 (en) Hair-mending compositions and associated methods
ZA201206718B (en) Pde10 inhibitors and related compositions and methods
GB0903299D0 (en) Composition and methods
IL214500A0 (en) Compositions and methods for extended therapy with aminopyridines
ZA201202561B (en) Compositions and methods for enhancing cognitive and related functions in animals
EP2410990A4 (en) Compositions and methods for enhancing contrast in imaging
EP2601269A4 (en) Anti-settling compositions and methods for use
GB201018650D0 (en) Methods and compositions
EP2205271A4 (en) Compositions and methods for ribonuclease-based therapies
HK1201451A1 (en) Compositions and methods
GB0901494D0 (en) Compositions and Methods
ZA201305086B (en) Methods and compositions useful for promoting sleep in animals
EP2461870A4 (en) Therapeutic compositions and methods
EP2504065A4 (en) Stable mixtures and related methods
ZA201201369B (en) Improvements in and relating to cable-barriers
GB2475090B (en) Fuels, methods of making them and additives for use in fuels
EP2498606A4 (en) Tivozanib and temsirolimus in combination
EP2723349A4 (en) Microrna-31 compositions and methods for use in autoimmune disease
GB0900329D0 (en) Improvements in anti-ligature devices and methods